Pioglitazone decreases hepatitis C viral load in overweight, treatment naïve, genotype 4 infected-patients: A pilot study

PLoS ONE

Volumn 7, Issue 3, 2012, Pages

  Chojkier, Mario ^a,b,c   Elkhayat, Hisham ^d,e   Sabry, Dina ^f   Donohue, Michael ^c   Buck, Martina ^a,b,c  

^a VA SAN DIEGO HEALTHCARE SYSTEM   (United States)

^b UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d THEODOR BILHARZ RESEARCH INSTITUTE   (Egypt)

^e MINISTRY OF HEALTH   (Egypt)

^f CAIRO UNIVERSITY   (Egypt)

Author keywords

[No Author keywords available]

Indexed keywords

PIOGLITAZONE; PREDNISONE; VIRUS RNA; 2,4 THIAZOLIDINEDIONE DERIVATIVE; ANTIVIRUS AGENT; CYTOKINE; PREDNISOLONE;

ADULT; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; DRUG TARGETING; EGYPT; FEMALE; GENOTYPE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; INSULIN RESISTANCE; INTERVENTION STUDY; MALE; OBESITY; PILOT STUDY; POPULATION RESEARCH; RANDOMIZED CONTROLLED TRIAL; REPLICON; VIRUS ENTRY; VIRUS INHIBITION; VIRUS LOAD; VIRUS REPLICATION; BLOOD; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DRUG EFFECT; GENETICS; GLUCOSE BLOOD LEVEL; METABOLISM; MIDDLE AGED; TOXIC HEPATITIS; TREATMENT OUTCOME; VIROLOGY;

HEPATITIS C VIRUS;

ADULT; ANTIVIRAL AGENTS; BLOOD GLUCOSE; CYTOKINES; DRUG-INDUCED LIVER INJURY; FEMALE; GENOTYPE; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; INSULIN RESISTANCE; MALE; MIDDLE AGED; OVERWEIGHT; PILOT PROJECTS; PREDNISOLONE; THIAZOLIDINEDIONES; TREATMENT OUTCOME; VIRAL LOAD;

EID: 84857891323     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0031516     Document Type: Article

References (35)

1. Mehta SH, Brancati FL, Strathdee SA, Pankow JS, Netski D, et al. (2003) Hepatitis C Virus Infection and Incidence Type 2 Diabetes. Hepatology 38: 50-56 10.1053/jhep.2003.50291.
2. White DL, Ratziu V, El-Serag HB, (2008) Hepatitis C infection and risk of diabetes: A systematic review and meta-analysis. Journal of Hepatology 49: 831-844 10.1016/j.jhep.2008.08.006.
3. Moucari R, Asselah T, Cazals-Hatem D, Voitot H, Boyer N, et al. (2008) Insulin resistance in chronic hepatitis C: association with genotypes 1 and 4, serum HCV RNA level, and liver fibrosis. Gastroenterology 134: 416-423.
4. Conjeevaram HS, Wahed AS, Afdhal N, Howell CD, Everhart JE, et al. (2011) Changes in Insulin Sensitivity and Body Weight During and After Peginterferon and Ribavirin Therapy for Hepatitis C. Gastroenterology 140: 469-477.
5. Romero-Gomez M, Del Mar Viloria M, Andrade RJ, Salmeron J, Diago M, et al. (2005) Insulin resistance impairs sustained response rate to peginterferon plus ribavirin in chronic hepatitis C patients. Gastroenterology 128: 636-641.
6. Torres DM, Harrison SA, (2008) Insulin resistance in chronic hepatitis C, genotypes 1 and 4: the unfortunate reality. Hepatology 47: 2137-2139.
7. Khattab M, Eslam M, Sharwae MA, Shatat M, Ali A, et al. (2010) Insulin resistance predicts rapid virologic response to peginterferon/ribavirin combination therapy in hepatitis C genotype 4 patients. American Journal of Gastroenterology 105: 1970-1977.
8. DeFronzo RA, Tripathy D, Schwenke DC, Banerji M, Bray GA, et al. (2011) Pioglitazone for Diabetes Prevention in Impaired Glucose Tolerance. New England Journal of Medicine 364: 1104-1115 10.1056/NEJMoa1010949.
9. Sanyal AJ, Chalasani N, Kowdley KV, McCullough A, Diehl AM, et al. (2010) Pioglitazone, Vitamin E, or Placebo for Nonalcoholic Steatohepatitis. New England Journal of Medicine 362: 1675-1685 10.1056/NEJMoa0907929.
10. Overbeck K, Genne D, Golay A, Negro F, Swiss Association for the Study of the Liver (SASL) (2008) Pioglitazone in chronic hepatitis C not responding to pegylated interferon-alpha and ribavirin. Journal of Hepatology 49: 295-298.
11. Khattab M, Emad M, Abdelaleem A, Eslam M, Atef R, et al. (2010) Pioglitazone improves virological response to peginterferon alpha-2b/ribavirin combination therapy in hepatitis C genotype 4 patients with insulin resistance. Liver International 30: 447-454.
12. Willi SM, Kennedy A, Wallace P, Ganaway E, Rogers NL, et al. (2002) Troglitazone antagonizes metabolic effects of glucocorticoids in humans: effects on glucose tolerance, insulin sensitivity, suppression of free fatty acids, and leptin. Diabetes 51: 2895-2902.
13. Ciesek S, Steinmann E, Iken M, Ott M, Helfritz FA, et al. (2010) Glucocorticosteroids increase cell entry by hepatitis C virus. Gastroenterology 138: 1875-1884.
14. Herzberg-Schafer SA, Staiger H, Heni M, Ketterer C, Guthoff M, et al. (2010) Evaluation of fasting state-/oral glucose tolerance test-derived measures of insulin release for the detection of genetically impaired ß-cell function. PLOS One 5: e14194.
15. Wagoner J, Austin M, Green J, Imaizumi T, Casola A, et al. (2007) Regulation of CXCL-8 (interleukin-8) induction by double-stranded RNA signaling pathways during Hepatitis C virus infection. Journal of Virology 81: 309-318.
16. Zeuzem S, (2008) Interferon-based therapy for chronic Hepatitis C: current and future perspectives. Nature Clinical Practice Gastroenterology & hepatology 5: 610-622.
17. Lincoff AM, Wolski K, Nicholls SJ, Nissen SE, (2007) Pioglitazone and risk of cardiovascular events in patients with Type 2 Diabetes Mellitus. A meta-analysis of randomized trials. JAMA 298: 1180-1188 10.1001/jama.298.10.1180.
18. Yokoo H, Kondo T, Fujii K, Yamada T, Todo S, et al. (2004) Proteomic signature corresponding to alpha fetoprotein expression in liver cancer cells. Hepatology 40: 609-617.
19. Vondracek SF, Hemstreet BA, (2006) Is there an optimal corticosteroid regimen for the management of an acute exacerbation of chronic obstructive pulmonary disease? Pharmacotherapy 26: 522-532.
20. Schulz KF, Altman DG, Moher D, for the CONSORT Group (2010) CONSORT 2010 Statement: Updated Guidelines for Reporting Parallel Group Randomised Trials. PLoS Med 7: e1000251 10.1371/journal.pmed.1000251.
21. Nguyen TT, Sedghi-Vaziri A, Wilkes LB, Mondala T, Pockros PJ, et al. (1996) Fluctations in viral load (HCV RNA) are relatively insignificant in untreated patients with chronic HCV infection. Journal of Viral Hepatitis 3: 75-78 10.1111/j.1365-2893.1996.tb00084.x.
22. Harrison SA, Hamzeh F, Han J, Vierling JM, (2011) Efficacy, Safety, and Metabolic Effects in Chronic Hepatitis C (CHC) Genotype 1 (G1) Patients With Insulin Resistance (IR) Treated With Pioglitazone (PIO) and Peginterferon Alfa-2a Plus Ribavirin (P/R). Hepatology 54: 439.
23. Conjeevaram H, Burant CF, McKenna B, Harsh D, Kang H, et al. (2008) A randomized, double-blind, placebo-controlled study of ppar-gamma agonist pioglitazone given in combination with peginterferon and ribavirin in patients with genotype-1 chronic hepatitis C. Hepatology 48: 384.
24. Harrison SA, (2006) Correlation between insulin resistance and hepatitis C viral load. Hepatology 43: 1168 10.1002/hep.21125.
25. Romero-Gómez M, Diago M, Andrade RJ, Calleja JL, Salmerón J, et al. (2009) Spanish Treatment of Resistance to Insulin in Hepatitis C Genotype 1 Group. Treatment of insulin resistance with metformin in naïve genotype 1 chronic hepatitis C patients receiving peginterferon alfa-2a plus ribavirin. Hepatology Dec;50 (6): 1702-8.
26. Serfaty L, Fartoux L, Poupon R, (2009) Pioglitazone as adjuvant therapy in chronic hepatitis C: Sequential rather than concomitant administration with pegylated interferon and ribavirin? Journal of Hepatology 50: 1269-1271 10.1016/j.jhep.2009.02.014.
27. Dharancy S, Lemoine M, Mathurin P, Serfaty L, Dubuquoy L, (2009) Peroxisome Proliferator- Activated Receptors in HCV-Related Infection. PPAR Res pp. 357204 doi:10.1155/2009/357204.
28. Kurihara T, Niimi A, Maeda A, Shigemoto M, Yamashita K, (2001) Study of effectiveness of bezafibrate in the treatment of chronic hepatitis C. The American Journal of Gastroenterology 96: 1659-1660.
29. Fujita N, Kaito M, Tanaka H, Horiike S, Adachi Y, (2004) Reduction of serum HCV RNA titer by bezafibrate therapy in patients with chronic hepatitis C. The American Journal of Gastroenterology 99: 2280.
30. Olefsky JM, Glass CK, (2010) Macrophages, inflammation and insulin resistance. Annual Review of Physiology 72: 219-246.
31. Galli A, Crabb DW, Ceni E, Salzano R, Svegliati-Baroni G, et al. (2002) Antidiabetic thiazolidinediones inhibit collagen synthesis and hepatic stellate cell activation in vivo and in vitro. Gastroenterology 122: 1924-1940.
32. Pesce JT, Ramalingam TR, Mentink-Kane MM, Wilson MS, El Kasmi KC, et al. (2009) Arginase-1-Expressing Macrophages Suppress Th2 Cytokine-Driven Inflammation and Fibrosis. PLoS Pathog 5: e1000371 10.1371/journal.ppat.1000371.
33. Duffield JS, Forbes SJ, Constandinou CM, Clay S, Partolina M, et al. (2005) Selective depletion of macrophages reveals distinct, opposing roles during liver injury and repair. J Clin Invest 115: 56-65.
34. Polyak SJ, Khabar KSA, Rezeiq M, Gretch DR, (2001) Elevated Levels of Interleukin-8 in Serum Are Associated with Hepatitis C Virus Infection and Resistance to Interferon Therapy. Journal of Virology 75: 6209-6211 10.1128/JVI.75.13.6209-6211.2001.
35. Thomas DL, Thio CL, Martin MP, Qi Y, Ge D, et al. (2009) Genetic variation in IL28B and spontaneous clearance of hepatitis C virus. Nature 461: 798-802 10.1038/nature08463.